Clinical Trials Browser

Interventional × Urinary Bladder Neoplasms × Cyclophosphamide × Clear all

NCT02869217 2025-12-03

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT04319757 2024-12-05

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Phase 1 Completed

12 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03836352 2022-03-31

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Phase 2 Active not recruiting

184 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Ovarian Neoplasms

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Phase 1/2 Terminated

3 enrolled 14 charts

BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT02457650 2016-08-03

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Phase 1 Unknown

36 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Synovial